Breaks Categories: News

MondayFeb 24, 2025 9:23 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Launches “CLD-101” Trial for High-Grade Glioma at Northwestern

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted antitumor virotherapies, said Northwestern University/Northwestern Memorial Hospital is recruiting for its Phase 1B/2 clinical trial of "CLD-101" in newly diagnosed high-grade glioma patients. The company completed shipment of the first batch of CLD-101—comprising allogeneic neural stem cells loaded with the oncolytic adenovirus CRAd-S-pk7—to support the trial, which builds on promising Phase 1 results in 12 patients published in The Lancet Oncology. The physician-led and NCI-sponsored study, headed by Dr Maciej Lesniak and Dr Roger Stupp and funded by the NIH/NCI SPORE, aims to evaluate a multiple-dose regimen that could…

Continue Reading

FridayFeb 21, 2025 8:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management will also be available for one-on-one meetings with registered investors, and a video webcast of the presentation will be accessible on-demand through the conference presenters portal. To view the full press release, visit https://ibn.fm/yGKfB About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central…

Continue Reading

ThursdayFeb 20, 2025 8:30 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry peers to follow the company in 2025. The presentation focused on CNS Pharmaceuticals’ advancements in developing treatments for primary and metastatic brain and central nervous system cancers, emphasizing its strategic initiatives and clinical progress for the year ahead. To view the full press release, visit https://ibn.fm/3gUjC About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic…

Continue Reading

WednesdayFeb 19, 2025 10:49 am

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) to Host Patient Forum on Alzheimer’s and Parkinson’s Trials

Annovis Bio (NYSE: ANVS) will host a live webcast on Feb. 27, 2025, at 4:30 p.m. EST, where CEO Maria Maccecchini, Ph.D., will answer questions from patients, caregivers, and families regarding the company’s clinical trials and future plans. The forum will provide updates on the ongoing Phase 3 Alzheimer’s disease trial, plans for the Phase 3 Parkinson’s disease study, and patient communication strategies. A brief presentation will precede a Q&A session, with attendees encouraged to submit questions in advance. The event underscores Annovis’ commitment to patient engagement and transparency. To view the full press release, visit https://ibn.fm/aFJV6 About Annovis Bio…

Continue Reading

WednesdayFeb 19, 2025 10:33 am

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 1-for-50 Reverse Stock Split

CNS Pharmaceuticals (NASDAQ: CNSP) announced a 1-for-50 reverse stock split of its common stock, set to take effect on Feb. 21, 2025. The company’s shares will continue trading on Nasdaq under the symbol “CNSP” but with a new CUSIP number: 18978H409. The reverse split aims to increase the per-share trading price and ensure compliance with Nasdaq’s minimum share price requirement. As a result, every 50 shares of common stock will be consolidated into one, with proportional adjustments made to outstanding equity awards and warrants. No fractional shares will be issued, with cash payments provided instead. The number of authorized shares…

Continue Reading

TuesdayFeb 18, 2025 12:46 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at 6th Glioblastoma Drug Development Summit

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the 6th Glioblastoma Drug Development Summit, taking place Feb. 18-20, 2025, in Boston. Chief Medical Officer Dr. Sandra Silberman will present on Feb. 20 at 10:45 a.m. ET, discussing novel formulations of anthracyclines and taxanes designed to cross the blood-brain barrier. The company’s lead candidate, Berubicin, has completed patient enrollment in a pivotal study against glioblastoma, with primary analysis data expected in the first half of 2025. CNS Pharmaceuticals is also advancing TPI 287 and plans to engage with the FDA on trial design. Berubicin has received Fast Track and Orphan Drug…

Continue Reading

ThursdayFeb 13, 2025 1:25 pm

BioMedNewsBreaks – Astiva Health Expands Community Engagement with New Activity Center in San Jose

Astiva Health announced the grand opening of its new Activity Center in San Jose, reinforcing its commitment to community wellness. The facility will serve as a hub for local seniors, offering various health and wellness programs designed to enhance quality of life. The initiative aligns with Astiva Health’s mission to provide accessible healthcare solutions and foster social engagement among its members. To view the full press release, visit https://ibn.fm/4Wlwb About Astiva Health Astiva is a leader in culturally responsive health care solutions, committed to bridging health care gaps for diverse and underserved populations. With a focus on delivering personalized care,…

Continue Reading

ThursdayFeb 13, 2025 12:02 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Prices $10 Million Public Offering at $1.70 Per Share

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care, announced the pricing of its public offering of 5,882,353 shares at $1.70 per share, expecting to raise $10 million before deductions. The offering, underwritten by MDB Capital with Paulson Investment Company LLC participating as a selected dealer, is set to close on or about Feb. 14, 2025, subject to conditions. Proceeds will support commercial-readiness efforts, R&D, clinical and regulatory projects, and general corporate purposes. The underwriter has a 45-day option to purchase up to 882,353 additional shares to cover over-allotments. To view the full press release, visit https://ibn.fm/wzvyh About…

Continue Reading

WednesdayFeb 12, 2025 2:05 pm

BioMedNewsBreaks – RenovoRx Inc. (NASDAQ: RNXT) Announces $12.1M Underwritten Public Offering

RenovoRx (NASDAQ: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath(R), a novel, FDA-cleared delivery platform, recently announced the pricing and closing of a firm commitment, underwritten public offering of 11,523,810 shares of its common stock at a price to the public of $1.05 per share. Of the approximately $12.1 million in gross proceeds, RenovoRx intends to use the net for working capital and general corporate purposes, including continued progression of its Phase III TIGeR-PaC study and the continued development and execution of commercial sales and marketing activities for RenovoCath as a standalone device. Titan Partners…

Continue Reading

TuesdayFeb 11, 2025 3:30 pm

BioMedNewsBreaks — Titan Partners Group Launches Equity Research Platform Led by Dr. Boris Peaker

Titan Partners, a division of American Capital Partners, today announced the launch of its Equity Research Division with the appointment of Boris Peaker, Ph.D., CFA, as managing director and senior equity research analyst. Dr. Peaker brings 17 years of experience in healthcare equity research and will lead the firm's research initiatives in the healthcare sector, focusing on biotechnology. “The launch of our research platform, spearheaded by Dr. Peaker, marks an important milestone in Titan’s growth,” said Jason Sands, co-founder and partner at Titan. “Our mission has always been to build a business around fundamentally strong and scientifically compelling stories. Dr.…

Continue Reading